

1 **IL-23 signaling prevents ferroptosis-driven renal immunopathology during candidiasis**

2 Nicolas Millet<sup>1,2</sup>, Norma V. Solis<sup>1,2</sup>, Diane Aguilar<sup>2</sup>, Michail S. Lionakis<sup>3</sup>, Robert T. Wheeler<sup>4</sup>,

3 Nicholas Jendzjowsky<sup>2</sup>, Marc Swidergall<sup>1,2,5\*</sup>

4 <sup>1</sup>Division of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, CA, USA

5 <sup>2</sup>The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA,

6 USA

7 <sup>3</sup>Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM),

8 National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA.

9 <sup>4</sup>Department of Molecular and Biomedical Sciences, University of Maine, Orono, Maine, USA

10 <sup>5</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

11 \*Correspondence: Marc Swidergall, [mswidergall@lundquist.org](mailto:mswidergall@lundquist.org)

12 **Abstract**

13 During infection the host relies on pattern-recognition receptors to sense invading fungal  
14 pathogens to launch immune defense mechanisms. While fungal recognition and immune effector  
15 responses are organ and cell type specific, during disseminated candidiasis myeloid cells exacerbate  
16 collateral tissue damage. However, the complex interplay between protective antifungal immunity  
17 and immunopathology remains incompletely understood. The  $\beta$ -glucan receptor ephrin type-A 2  
18 receptor (EphA2) is required to initiate mucosal inflammatory responses during oral *Candida*  
19 infection. Here we report that EphA2 promotes renal immunopathology during disseminated  
20 candidiasis. EphA2 deficiency leads to reduced renal inflammation and injury. Comprehensive  
21 analyses reveal that EphA2 limits IL-23 secretion in dendritic cells, while IL-23 signaling prevents  
22 ferroptotic myeloid cell death during infection. Further, ferroptosis aggravates inflammation during  
23 infection, while at the same time reducing the fungal killing capacity of macrophages. Thus, we  
24 identify ferroptotic cell death as a critical pathway of *Candida*-mediated renal immunopathology  
25 that opens a new avenue to tackle *Candida* infection and inflammation.

26 **Introduction**

27 The first step in mounting an antifungal immune response is the recognition of extracellular  
28 pathogen-associated molecular patterns (PAMPs) of invading organism, such as *Candida*  
29 *albicans*, by various families of soluble and membrane-bound pattern recognition receptors  
30 (PRRs) <sup>1,2</sup>. Following recognition, the effective control of *C. albicans* relies on several effector  
31 mechanisms and cell types to ensure fungal clearance <sup>3-9</sup>. In contrast to mucosal candidiasis, in which  
32 IL-17-producing lymphocytes are crucial for host defense <sup>10-14</sup>, effective immunity during disseminated  
33 candidiasis relies on myeloid phagocytes <sup>2,15-17</sup>. Although myeloid phagocytes are crucial for host  
34 defense during disseminated candidiasis, their functions that are aimed to control fungal infections  
35 may also come at the cost of immunopathology <sup>18,19</sup>. In fact, excessive neutrophil accumulation in  
36 tissues late in the course of infection is deleterious in mouse models of disseminated candidiasis <sup>17,20</sup>.

37 *C. albicans* is known to induce tissue injury and host cell death <sup>17,18,21</sup>, e.g. in the kidney, a  
38 major target organ during disseminated candidiasis. Regulated host cell death (RCD) results in  
39 either lytic or non-lytic morphology, depending upon the signaling pathway <sup>22</sup>. Apoptosis is a non-  
40 lytic, and typically immunologically silent form of cell death <sup>23</sup>. On the other hand, lytic cell death  
41 is highly inflammatory <sup>23-26</sup>, and includes necroptosis (alternative mode of RCD mimicking features  
42 of apoptosis and necrosis <sup>27</sup>), pyroptosis (RCD driven by inflammasome activation <sup>22</sup>), and  
43 ferroptosis (iron- and lipotoxicity-dependent form of RCD <sup>25</sup>). Inflammatory RCD depends on the  
44 release of damage-associated molecular pattern (DAMPs) and inflammatory mediators <sup>28</sup>. RCD is  
45 increasingly understood to benefit the host <sup>29</sup>, and *C. albicans* is known to induce inflammatory  
46 RCDs, such as necroptosis, and pyroptosis to promote inflammation <sup>30,31</sup>. Indeed, deficiencies in  
47 these pathways accelerate disease progression during fungal infection <sup>31,32</sup>. However, excessive  
48 inflammation results in renal immunopathology during candidiasis suggesting that other  
49 mechanisms or RCDs fine-tune immunopathology and fungal control. Emerging data from various  
50 studies indicate an essential function of non-classical  $\beta$ -glucan recognition during fungal  
51 infections <sup>33-38</sup>. We recently found that EphA2 acts as a  $\beta$ -glucan receptor in the oral cavity that

52 triggers the production of pro-inflammatory mediators via STAT3 and MAPK on oral epithelial cells,  
53 while EphA2 induces priming of neutrophil p47<sup>phox</sup> to increase intracellular reactive oxygen species  
54 (ROS) production to enhance killing of opsonized *C. albicans* yeast<sup>33,34</sup>. Although the function of this  
55 novel β-glucan receptor EphA2 is well established during oral mucosal *C. albicans* infection<sup>33,34,39-41</sup>,  
56 the role of EphA2 during disseminated candidiasis is unknown.

57 **Results**

58 **EphA2 deficiency increases tolerance during disseminated candidiasis**

59 Being the core of the immune response, professional immune cells act as the most  
60 effective weapon to clear invading fungi. Dectin-1/CLEC7A is a major PRR of the C-type lectin  
61 family, predominantly expressed on myeloid-derived cells. Classical β-glucan recognition by  
62 Dectin-1 activates fungal phagocytosis and the production of pro-inflammatory cytokines<sup>4,42</sup>.  
63 Consistent with previous findings<sup>43,44</sup>, Dectin-1 deficiency results in increased mortality in a  
64 mouse model of disseminated candidiasis (**Fig. 1A**). Although EphA2 recognizes β-glucan<sup>33,38</sup>,  
65 and EphA2 deficiency results in increased susceptibility to oral fungal infection<sup>33,34,40</sup>, *EphA2*<sup>-/-</sup>  
66 mice were more resistant during lethal *C. albicans* challenge (**Fig. 1B, C**). Since EphA2 is  
67 expressed on both stromal and hematopoietic cells<sup>33,34,37,45,46</sup>, we generated bone marrow (BM)  
68 chimeric mice and determined their resistance to disseminated candidiasis (**Fig. S1**).  
69 Both, *EphA2*<sup>+/+</sup> mice reconstituted with *EphA2*<sup>-/-</sup> BM (knockout (KO)→wild-type (WT))  
70 and *EphA2*<sup>-/-</sup> mice reconstituted with *EphA2*<sup>+/+</sup> BM (WT→KO) were more resistant during HDC  
71 compared to *EphA2*<sup>+/+</sup> mice reconstituted with *EphA2*<sup>+/+</sup> BM (WT→WT) (**Fig. 1D**). However, these  
72 chimeric mice were more susceptible than *EphA2*<sup>-/-</sup> mice reconstituted with *EphA2*<sup>-/-</sup> BM  
73 (KO→KO), which recapitulated the phenotype observed in global *EphA2*<sup>-/-</sup> mice (**Fig. 1B**),  
74 suggesting that EphA2 deficiency within cells of both, the hematopoietic and stromal  
75 compartments, is required for full protection against disseminated candidiasis.

76 Kidneys are a primary target organ of *C. albicans*, and invasion into the kidney medulla leads  
77 to loss of renal function and death<sup>47,48</sup>. Therefore, we determined the kidney fungal burden 4 days  
78 post infection. Strikingly, no differences in renal fungal burden could be observed after 4 days of  
79 infection (**Fig. 1E**). We have previously shown that EphA2 activation triggers receptor-mediated  
80 invasion of oral epithelial cells<sup>33,40</sup>. The mouse model of disseminated candidiasis leads to rapid organ  
81 dissemination and clearance of >99% of the fungus from the bloodstream within the first hour after  
82 intravenous injection<sup>49</sup>, while *C. albicans* mutants defective in invasion have reduced kidney fungal  
83 burden<sup>50,51</sup>. To rule out a possible decrease of dissemination out of the bloodstream we collected  
84 kidneys from WT and *EphA2*<sup>-/-</sup> mice 12 hours post infection and enumerated fungal burden.  
85 Resistance and tolerance are two complementary host defense mechanisms that increase host  
86 fitness in response to invading *C. albicans*<sup>52</sup>. Since WT and *EphA2*<sup>-/-</sup> mice had similar renal fungal  
87 burden (**Fig. 1F**), we concluded that EphA2 deficiency enhances host tolerance, independent of  
88 fungal trafficking out of the bloodstream. Although EphA2 enhances neutrophilic killing of opsonized  
89 yeast<sup>34</sup>, EphA2 has no effect on elimination of hyphae (**Fig. S2**), which are the dominant  
90 morphotype in kidneys after 12 hours of systemic infection (**Fig. S2**).

91 Severe renal failure plays a major role in lethality of systemic *C. albicans* infection<sup>9,53-55</sup>.  
92 Therefore, we determined apoptotic areas in kidneys of WT and *EphA2*<sup>-/-</sup> mice infected *C. albicans*  
93 using terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining<sup>48</sup>. Although  
94 apoptosis could be detected in kidneys of both mouse strains, the overall apoptotic areas decreased  
95 in infected *EphA2*<sup>-/-</sup> mice (**Fig. 1G; Fig S3**). Next, we assessed serum neutrophil gelatinase-  
96 associated lipocalin (NGAL), a marker of acute kidney injury<sup>48,56</sup>. NGAL was strongly present in serum  
97 of WT mice, while this kidney injury marker was reduced in *EphA2*<sup>-/-</sup> mice (**Fig. 1H**). During  
98 disseminated candidiasis, both systemic inflammation as well as rapid deterioration of the infected  
99 host resembles hyper-inflammatory sepsis<sup>57</sup>. Therefore, we measured the sepsis marker soluble  
100 triggering receptor expressed on myeloid cells (TREM1)<sup>58</sup> in serum of infected mice. TREM1 was  
101 significantly reduced in *EphA2*<sup>-/-</sup> mice compared to WT mice (**Fig. 1I**). Given that EphA2 promotes

102 inflammation during oral *C. albicans* infection<sup>33,34,39-41</sup>, we assessed the contribution of EphA2 in a  
103 mouse model of zymosan ( $\beta$ -glucan) - induced acute kidney injury (AKI), in which immune cells and  
104 inflammation exert essential roles in kidney damage<sup>59,60</sup>. We found that EphA2 deficient mice were  
105 more resistant to AKI (**Fig. 1J**). Together, this data suggest that EphA2 promotes inflammation to  
106 accelerate disease progression during disseminated candidiasis.

### 107 **EphA2 promotes renal inflammation during disseminated candidiasis**

108 Although the host immune response is required to control *C. albicans* infections, the  
109 inflammatory response causes significant collateral tissue damage. Therefore, we determined the  
110 cytokine and chemokine response in infected kidneys in WT and *EphA2*<sup>-/-</sup> mice. *EphA2*<sup>-/-</sup> mice had  
111 reduced kidney levels of several pro-inflammatory cytokines, including TNF $\alpha$ , IL-1 $\beta$ , and IL-6 (**Fig.**  
112 **2A**). By contrast, we found that *EphA2*<sup>-/-</sup> mice had increased levels of IL-23, IFN $\gamma$ , and IL-4 (**Fig.**  
113 **2B**). Next, we assessed renal leukocyte infiltration during infection. *EphA2*<sup>-/-</sup> mice had decreased  
114 accumulation of neutrophils and monocytes (**Fig. 2C**; **Fig. S4**), but no differences in macrophage  
115 accumulation was observed (**Fig. 2C**). Consistent with previous observations, EphA2 deficiency  
116 increased the accumulation of dendritic cells (DCs) during infection<sup>61</sup> (**Fig. 2D-F**). These  
117 experiments suggested that EphA2 is critical to promote renal inflammation during disseminated  
118 candidiasis.

### 119 **EphA2 deficiency reduces renal ferroptosis during disseminated candidiasis**

120 To comprehensively evaluate the transcriptional response of *EphA2*<sup>-/-</sup> mice during *C. albicans*  
121 infection, we performed RNA sequencing of infected kidneys. Consistent with our findings that EphA2  
122 deficient mice had reduced renal apoptosis (**Fig. 1G**) and reduced inflammation (**Fig. 2**), KEGG  
123 pathway analysis revealed downregulation of genes involved in apoptosis and several immune  
124 response pathways (**Fig. 3A**). Using Gene Set Enrichment Analysis (GSEA) we found that genes  
125 involved in ferroptosis were significantly enriched in infected kidneys from WT mice compared to  
126 *EphA2*<sup>-/-</sup> mice (**Fig. 3B**). In tumor cells, SLC7A11-mediated cystine uptake promotes GPX4 protein  
127 synthesis to reduce sensitivity to ferroptotic cell death<sup>62,63</sup>. Therefore, we determined the two anti-

128 ferroptotic genes *SLC7a11* and *GPX4*, as well as *LYZ2*, a myeloid cell lineage marker, using  
129 RNAscope (**Fig. 3C**). *SLC7a11* and *GPX4* RNAscope particles were reduced in infected kidneys from  
130 *Epha2*<sup>-/-</sup> mice (**Fig. 3D**). Furthermore, *GPX4* particles in myeloid cells were enriched in kidney  
131 sections from WT compared *Epha2*<sup>-/-</sup> mice (**Fig. 3E**). Using immunofluorescence, we confirmed that  
132 *GPX4* protein expression was reduced in *Epha2*<sup>-/-</sup> mice in infected tissue (**Fig. 3F**). Ferroptosis is a  
133 lipid peroxidation-driven form of RCD<sup>64</sup>. Therefore, we determined the level of lipid peroxidation using  
134 4-hydroxynonenal (4HNE) staining. While kidney sections of WT mice showed strong lipid  
135 peroxidation, sections of *Epha2*<sup>-/-</sup> mice had low levels of ferroptosis (**Fig. 3G**) suggesting that during  
136 infection host cells undergo excessive lipid peroxidation although anti-ferroptotic mechanisms are  
137 upregulated. Since *LYZ2*<sup>-/-</sup> cells in kidney sections from WT and *Epha2*<sup>-/-</sup> mice had comparable *GPX4*  
138 expression, we tested whether EphA2 deficiency in macrophages (*LYZ2*<sup>+</sup>) results in decreased  
139 ferroptosis. Using the lipid peroxidation sensor BODIPY, as well as 4HNE staining, we showed that  
140 BMDMs from *Epha2*<sup>-/-</sup> mice underwent similar magnitudes of ferroptosis compared to WT BMDMs  
141 (**Fig. S5**). Collectively, this data suggest that EphA2 promotes ferroptotic cell death via an extrinsic  
142 pathway during candidiasis.

#### 143 **Ferroptotic cell death exerts inflammation and promotes disease severity during candidiasis**

144 To investigate whether ferroptotic cell death exacerbates inflammation and disease  
145 progression during fungal infection, we first determined that *C. albicans* induces ferroptosis in bone  
146 marrow-derived macrophages (BMDMs) (**Fig. 4A**) and renal tubular epithelial cells (RTECs) (**Fig.**  
147 **4B**). Inhibition of ferroptosis using the selective inhibitor Ferrostatin-1 (Fer-1)<sup>65</sup> increased survival of  
148 BMDMs and RTECs during *C. albicans* interactions (**Fig. 4C, D; Fig. S6**). This finding is  
149 consistent with previous reports showing that Fer-1 treatment reduces macrophage cell death  
150 during *Histoplasma capsulatum* infection<sup>66</sup>. Increased BMDM survival was associated with  
151 increased *C. albicans* killing (**Fig. 4E**). Furthermore, inhibition of ferroptosis reduced cytokine  
152 secretion in BMDMs (**Fig. 4F**) and RTECs (**Fig. 4G**) suggesting that ferroptosis exerts inflammation  
153 during *C. albicans* infection. To analyze the contribution of ferroptotic cell death to the pathogenicity

154 of disseminated candidiasis, we infected WT mice with *C. albicans* followed by daily treatment with  
155 Fer-1. Mice treated with Fer-1 were less susceptible to *C. albicans* challenge compared to vehicle  
156 control mice (**Fig. 4H, I**). Collectively, disseminated candidiasis induces ferroptosis in various host  
157 cell types to promote inflammation and disease progression.

158 **EphA2 and JAK signaling limit IL-23 secretion in DCs**

159 Following systemic *C. albicans* infection, DCs produce IL-23 to stimulate natural killer (NK)  
160 cell activity <sup>8</sup>. Accordingly, renal IL-23 levels correlated with increased cDC infiltration during  
161 infection in *EphA2*<sup>-/-</sup> mice (**Fig. 5A**). DCs derived from *EphA2*<sup>-/-</sup> BM secreted more IL-23 when  
162 stimulated with  $\beta$ -glucan (**Fig. 5B**), while TNF $\alpha$  levels were unaffected (**Fig. S7**). Next, we  
163 examined the transcriptional response of  $\beta$ -glucan stimulated DCs using RNA sequencing. KEGG  
164 pathway mapping revealed downregulation of genes associated with Janus-associated kinase  
165 (JAK)- Signal transducers and activators of transcription (STAT) signaling in *EphA2*<sup>-/-</sup> BMDCs,  
166 while genes of the peroxisome proliferator-activated receptors (PPAR) pathway were upregulated  
167 (**Fig. 5C**). To investigate the contribution of JAK-STAT and PPAR signaling to IL-23 secretion in  
168 DCs, we treated WT BMDCs with Ruxolitinib (JAK1/2 inhibitor), the PPAR $\gamma$  antagonist GW9662,  
169 and the PPAR $\gamma$  agonist Rosiglitazone followed by  $\beta$ -glucan stimulation. While PPAR $\gamma$  stimulation  
170 or inhibition had no effect on IL-23 secretion, Ruxolitinib increased IL-23 levels in supernatants  
171 during  $\beta$ -glucan stimulation (**Fig. 5D**). This experiment suggested that  $\beta$ -glucan-induced JAK-  
172 STAT signaling reduces IL-23 secretion in DCs.

173 **IL-23 inhibits ferroptosis during disseminated candidiasis**

174 Besides stimulating NK cells <sup>8</sup>, IL-23 secures myeloid cell survival during candidiasis <sup>67</sup>. It  
175 is thought that this mechanism is key for maintaining sufficient numbers of phagocytes at the site  
176 of infection to ensure efficient host protection <sup>67</sup>. The link between myeloid cell survival and IL-23  
177 was intriguing since IL-23 receptor downstream targets have been associated to counteract  
178 ferroptotic cell death <sup>68,69</sup>. To test if IL-23 prevents macrophage ferroptosis during *C. albicans*  
179 infection, we measured total cell fluorescence of oxidized C11-BODIPY. Exogenous IL-23

180 reduced macrophage lipid peroxidation during *C. albicans* interaction (**Fig. 6A**). Furthermore,  
181 treatment with IL-23 increased macrophage survival (**Fig. 6B**), their *C. albicans* killing capacity  
182 (**Fig. 6C**), and reduced inflammation (**Fig. 6C**), as seen in macrophages treated with the  
183 ferroptosis inhibitor (**Fig. 4**). This data suggested that IL-23 signaling reduces ferroptotic  
184 macrophage cell death during *C. albicans* infection. Next, we treated *Candida*-infected WT mice  
185 with recombinant murine IL-23 for 3 consecutive days (**Fig. 6D**). IL-23 treatment increased the  
186 median survival by >65% (6 vs. 10 days) (**Fig. 6D**) and reduced the renal fungal burden (**Fig. 6E**).  
187 We determined ferroptosis in infected kidneys by staining section for 4HNE. Treatment with rmIL-23  
188 decreased lipid peroxidation compared to PBS control (**Fig. 6G**). Collectively, we show that IL-23  
189 signaling prevents inflammatory ferroptosis in myeloid cells and improves disease outcomes during  
190 disseminated candidiasis.

191 **Discussion**

192 Distinct RCD mechanisms promote the resolution of infection by destroying intracellular  
193 niches which benefit the pathogen, and to coordinate an appropriate innate immune response  
194 thereafter <sup>23</sup>. However, the RCD ferroptosis has been implicated in the development of many  
195 diseases <sup>70-72</sup>. Although inflammation is required to fight infections, a reduction in myeloid cell-  
196 mediated immunopathology may lead to pathogen tolerance, a phenomenon whereby the host is able  
197 to better resist infection by reducing tissue damage <sup>18,73</sup>. Our findings uncover a mechanism linking  
198 ferroptosis to immunopathology during candidiasis (**Fig. S8**). Here we show that myeloid and  
199 stromal cells undergo ferroptotic RCD to accelerate inflammation during fungal encounter.  
200 Macrophage ferroptosis is limited by exogenous IL-23; thus safeguarding efficient fungal  
201 clearance and controlled inflammation.

202 While the production of reactive oxygen species (ROS) is a key aspect of phagocyte-  
203 mediated host responses during *C. albicans* infection, an increase in ROS may cause lipid  
204 peroxidation and ferroptosis <sup>74</sup>. Here, we show that ferroptotic cell death benefits fungi by reducing

205 the killing capacity of macrophages. Lipid peroxidation during ferroptosis results in production of  
206 4HNE and malondialdehyde (MDA), which are able to react with primary amines on proteins or  
207 DNA to form crosslinks <sup>75</sup>. Exogenous 4HNE impairs the PKC signaling pathway in RAW  
208 macrophages <sup>76</sup>, a critical mediator of antifungal host defense <sup>77</sup>. The contribution of lipid  
209 peroxides and their degradation products to immune signaling and antifungal defense both,  
210 intrinsic and extrinsic, is being further investigated.

211 In response to reduced inflammatory signals, classical macrophages (M1 state) are more  
212 resistant to pro-ferroptotic treatment with a specific GPX4 inhibitor <sup>78</sup>. However, sensitization to  
213 ferroptotic cell death is regulated by various mechanical stimuli <sup>79</sup>. Protrusive force is generated  
214 during phagocytosis <sup>80</sup>, and immune cells respond to mechanical forces during the polarized  
215 growth of fungal hyphae <sup>81</sup>. Likewise, fungal  $\beta$ -glucan recognition induces mTOR signaling in  
216 monocytes <sup>82</sup>, which has been associated with increased sensitivity to ferroptosis <sup>83</sup>. Hence,  
217 mechanical forces during infection and consequently activation of distinct downstream signaling  
218 pathways sensitize myeloid cells to undergo ferroptotic cell death.

219 IL-23 has received significant interest as a therapeutic target for a number of autoimmune  
220 conditions in recent clinical trials <sup>84</sup>. However, IL-23 has established roles during antifungal  
221 immunity <sup>85</sup>. IL-23 expression is strongly induced in response to *C. albicans* via the C-type lectin  
222 and TLR pathways <sup>86</sup> and is best known for regulating IL-17 production by T cells and innate  
223 lymphoid cells at epithelial barriers <sup>84</sup>. IL-23 binds to IL-12R $\beta$ 1 and IL-23R followed by receptor  
224 complex signaling via JAK2 and Tyk2 <sup>85,87,88</sup>. In a mouse model of disseminated candidiasis, pre-  
225 treatment with tofacitinib <sup>89</sup> and ruxolitinib <sup>90</sup> (JAK inhibitors) increase susceptibility and fungal  
226 burden, while inflammation increases when therapy is started at the onset of disease <sup>90</sup>.  
227 Furthermore, the IL-23 signaling cascade activates several STAT members, including STAT3 <sup>91,92</sup>.  
228 In tumor cells, STAT3 inhibition induces ferroptosis via Nrf2-GPX4 signaling <sup>68</sup>, while STAT3  
229 activation suppresses expression of ACSL4, an enzyme that enriches membranes with long  
230 polyunsaturated fatty acids and is required for ferroptosis <sup>69</sup>. Nur *et al.* showed that IL-23 secures

231 survival of myeloid cells during candidiasis by inhibiting apoptosis <sup>67</sup>. Here, we demonstrate a  
232 non-canonical role of IL-23 signaling in inhibiting macrophage ferroptosis during fungal infection.  
233 Historically, cell death pathways have long been considered to function in parallel with little or no  
234 overlap. However, it is currently known that lytic and non-lytic RCDs, such as apoptosis,  
235 necroptosis, pyroptosis, and ferroptosis are tightly connected, and can cross-regulate each other  
236 <sup>22</sup>. For instance STAT3 activation (downstream of IL-23R) limits ferroptosis, pyroptosis, and  
237 necroptosis <sup>68,93,94</sup>. This suggest that different types of cell death depend on the stimulant, either  
238 infectious agent or drug, the cell type, and the environment, but share similar downstream signals  
239 and molecular regulators.

240 While IL-23 inhibits ferroptotic cell death in macrophages, some cytokines, such as INF $\gamma$ ,  
241 drive ferroptosis via STAT1 signaling in tumor cells <sup>95</sup>. Whether the inflammatory tissue  
242 environment during infection and their corresponding cytokines sensitize immune cells to  
243 ferroptotic cell death needs to be determined. Although ferroptotic cells exhibit phosphatidylserine  
244 surface exposure, which triggers removal of dying cells by macrophages <sup>96</sup>, ferroptotic cells are  
245 poorly engulfed and cleared <sup>97</sup>. Thus, we speculate that inefficient clearance of ferroptotic immune  
246 cells might accelerate immunopathology during infection.

247 In DCs  $\beta$ -glucan recognition induces several signaling pathways, including AKT, MAPKs,  
248 IKK, and NF- $\kappa$ B <sup>86</sup>. Here we show that activation of the  $\beta$ -glucan receptor EphA2 represses IL-23  
249 secretion suggesting that  $\beta$ -glucan recognition stimulates IL-23 expression via Dectin-1/TLR-2 <sup>98</sup>,  
250 but limits the cytokine secretion via non-classical  $\beta$ -glucan recognition. EphA2 activates  
251 JAK1/STAT3 signaling <sup>99</sup>, and STAT3 deficient DCs exhibit increased IL-23 production after  
252 stimulation <sup>100</sup>. Accordingly, EphA2 deficient DCs and inhibition of JAK signaling in  $\beta$ -glucan  
253 stimulated DCs increase IL-23 secretion. Taken together, EphA2-JAK-STAT signaling negatively  
254 regulates an inflammatory IL-23 DC phenotype during fungal encounter

255 Collectively, our study demonstrates that ferroptotic host cell death is linked to  
256 immunopathology and can be targeted by recombinant cytokine therapy during fungal infection.

257 We postulate that strategies to inhibit ferroptotic cell death during infection will have important  
258 therapeutic benefits.

259 **Methods**

260 **Ethics statement.** All animal work was approved by the Institutional Animal Care and Use  
261 Committee (IACUC) of the Lundquist Institute at Harbor-UCLA Medical Center.

262 **Subject details.** For *in vivo* animal studies, age-and sex matched mice were used. Animals were  
263 bred/housed under pathogen-free conditions at the Lundquist Institute. Animals were randomly  
264 assigned to the different treatment groups. Researchers were not blinded to the experimental  
265 groups because the endpoints (survival, fungal burden, cytokine levels) were objective measures  
266 of disease severity. *Epha2*<sup>-/-</sup> (B6-*Epha2*<sup>tm1Jru</sup>/J) mice were provided by A. Wayne Orr<sup>46</sup>. C57BL/6  
267 control and *Clec7a*<sup>-/-</sup> mice were purchased from The Jackson Laboratory. All mice were cohoused  
268 for at least 1 week before the experiments.

269 **Mouse model of HDC.** Resistance to disseminated candidiasis was tested in the mouse model  
270 of HDC using 6- to 8-week-old mice (C57BL/6J background) as previously described<sup>17</sup>. The  
271 *C. albicans* SC5314 strain was serially passaged 3 times in YPD broth, grown at 30°C at 200 rpm  
272 for 16–24 hours at each passage. Yeast cells were washed, and 2.5x 10<sup>5</sup> or 1.25x10<sup>5</sup> *C. albicans*  
273 cells injected intravenously via the lateral tail vein. For survival experiments, mice were monitored  
274 three times daily and moribund mice were humanely euthanized. To determine organ fungal  
275 burden, mice were sacrificed after 12 hours and 4 days of infection, after which the kidneys were  
276 harvested, weighed, homogenized, and quantified on sabouraud dextrose agar plates containing  
277 80 mg/L chloramphenicol. For histology, mouse kidneys were fixed in 10% buffered formalin and  
278 embedded in paraffin.

279 To inhibited ferroptosis during infection mice were treated daily intraperitoneally (start 6  
280 hours post infection) with 10 mg/kg Ferrostatin-1 (SelleckChem; >99% purity) dissolved in 0.9%  
281 NaCl. In another experiment mice were treated intravenously 2 days post infection with 12.5 µg/kg  
282 recombinant murine IL-23 (1887-ML-010/CF, R&D Systems) for 3 consecutive days.

283 **Immunohistochemistry.** Apoptotic cell death was determined as previously described<sup>48</sup>. Briefly,  
284 terminal deoxynucleotidyl transferase nick end labeling (TUNEL) staining was performed using

285 the *in situ* apoptosis detection kit (ApopTag, S7100, Chemicon, Temecula, CA, USA) according  
286 to the manufacturer's protocol with minor modifications. The paraffin-embedded renal sections  
287 were placed on poly-L-lysine coated glass slides, deparaffinized in xylene and rehydrated in a  
288 graded series of alcohol. Then treated with protease K (20 g/ml) for 15 min at room temperature.  
289 Sections were incubated with reaction buffer containing terminal deoxynucleotidyltransferase at  
290 37°C for 1 h. After washing with stop/wash buffer, sections were treated with anti-digoxigenin  
291 conjugate for 30 min at room temperature and subsequently developed color in peroxidase  
292 substrate. The nuclei were counterstained with 0.5% methyl green. TUNEL-positive cells/areas  
293 were determined by bright field microscopy. For quantification, apoptotic areas were quantified  
294 using PROGRES GRYPHAX® software (Jenoptik).

295 To determine GPX4 and 4HNE expression, kidneys of WT and *Epha2*<sup>-/-</sup> mice were  
296 harvested 3 days post infection, and snap frozen in Tissue-Tek® OCT. 10 µm kidney sections  
297 were fixed with cold acetone, rehydrated in PBS, blocked with BSA, and stained overnight using  
298 anti-GPX4 or anti-4HNE (ab125066 and ab46545, respectively). Sections were washed and  
299 incubated with anti-rabbit IgG (H+L) coupled with Alexa Fluor™ 488 (Thermo Fisher Scientific).  
300 *C. albicans* was detected with an anti-*Candida* antiserum (Biodesign International) conjugated  
301 with Alexa Fluor 568 (Thermo Fisher Scientific). To visualize nuclei, cells were stained with DAPI  
302 (Prolong Gold antifade reagent with DAPI). Images of the sections (z-stack) were acquired with a  
303 Leica TCS SP8 confocal microscope. To enable comparison of the fluorescence intensities  
304 among slide, the same image acquisition settings were used for each experiment.

305 **Determination of serum NGAL and TREM-1.** Serum NGAL and TREM-1 were measured at day  
306 3 post-infection. Blood was collected by cardiac puncture from each mouse at the time of sacrifice,  
307 and stored at -80°C until use. NGAL and TREM-1 concentrations were determined using DuoSet  
308 ELISA Kit (DY1857-05 & DY1187, R&D Systems).

309 **Cytokine and chemokine measurements *in vivo*.** To determine the whole kidney cytokine and  
310 chemokine protein concentrations, the mice were intravenously infected with *C. albicans* SC5314.

311 The mice were sacrificed after 3 days post-infection, and their kidney were harvested, weighed  
312 and homogenized. The homogenates were cleared by centrifugation and the concentration of  
313 inflammatory mediators was measured using the Luminex multiplex bead assay (Invitrogen).  
314 **Generation of BM chimeric mice.** Bone marrow chimeric mice were generated as previously  
315 described<sup>34</sup>. Briefly, for BM cell transfers, femurs and tibias from 6- to 8-week-old donor wild-type  
316 (*Epha2*<sup>+/+</sup>; CD45.1, or CD45.2) and *Epha2*<sup>-/-</sup> (CD45.2) mice were removed aseptically and BM  
317 was flushed using cold PBS supplemented with 2 mM EDTA. Recipient wild-type (CD45.1;  
318 B6.SJL-*Ptprc*<sup>a</sup> *Pepc*<sup>b</sup>/BoyJ) and *Epha2*<sup>-/-</sup> mice were irradiated with 10 Gy and were reconstituted  
319 6 hours after irradiation with 2.5x10<sup>6</sup> *Epha2*<sup>+/+</sup> CD45.2 (WT→WT), *Epha2*<sup>+/+</sup> CD45.1 (wild-  
320 type→*Epha2*<sup>-/-</sup>), or *Epha2*<sup>-/-</sup> CD45.2 BM cells by lateral tail-vein injection. Mice were given  
321 enrofloxacin (Victor Medical) in the drinking water for the first 4 weeks of reconstitution before  
322 being switched to antibiotic-free water. Chimeras were infected with *C. albicans* 10 weeks after  
323 transplantation. Prior to infection, we confirmed that mice reconstituted with congenic BM stem  
324 cells had achieved a satisfactory level of chimerism by assessing the number of CD45.1 and  
325 CD45.2 leukocytes in the blood, using flow cytometry (**Fig. S1**).

326 **Flow cytometry of infiltrating leukocytes.** Immune cells in the mouse kidney were  
327 characterized as described. Briefly, mice were infected with *C. albicans* strain SC5314. After 3  
328 days of infection, mice were anesthetized using ketamine/xylazine and perfused with 10 ml of  
329 PBS before kidney harvesting. Single-cell suspensions from kidney were prepared using  
330 previously described methods<sup>101</sup>. In brief, kidneys were finely minced and digested at 37°C in  
331 digestion solution (RPMI 1640 with 20 mM HEPES [Gibco] without serum) containing liberase TL  
332 (Roche) and grade II DNase I (Roche) for 20 minutes with shaking. Digested tissue was passed  
333 through a 70-μm filter and washed. The remaining red blood cells were lysed with ACK lysis buffer  
334 (Lonza). The cells were suspended in 40% Percoll (GE Healthcare). The suspension was overlaid  
335 on 70% Percoll and centrifuged at 836 g for 30 minutes at room temperature. The leukocytes and  
336 nonhematopoietic cells at the interphase were isolated, washed 3 times in FACS buffer (0.5%

337 BSA and 0.01% NaN<sub>3</sub> in PBS). The single-cell suspensions were then incubated with rat anti-  
338 mouse CD16/32 (2.4G2; BD Biosciences) for 10 minutes (1:100) in FACS buffer at 4°C to block  
339 Fc receptors. For staining of surface antigens, cells were incubated with fluorochrome-conjugated  
340 (BV421, BV711, FITC, PE, PE-Cy7, allophycocyanin [APC], APC-Cy7) antibodies against mouse  
341 CD45 (30-F11; BD Biosciences), Ly6C (AL-21; BD Biosciences), Ly6G (1A8, BioLegend), CD11b  
342 (M1/70; eBioscience), CD11c (N41, BioLegend), MHCII (M5/114.15.2, BioLegend), and CD206  
343 (C068C2; BioLegend). After washing with FACS buffer, the cell suspension was stained with a  
344 Fixable Viability Stain 510 (BD Biosciences), washed, and resuspended in FACS buffer. The  
345 stained cells were analyzed on a FACSsymphony system (BD Biosciences), and the data were  
346 analyzed using FACS Diva (BD Biosciences) and FlowJo software (Treestar). Only single cells  
347 were analyzed, and cell numbers were quantified using PE-conjugated fluorescent counting  
348 beads (Spherotech).

349 **RNA Sequencing.** Total RNA was isolated as described before <sup>102</sup>. Briefly, kidneys from infected  
350 mice were harvested at 3 days post infection and placed for 1 hour in RNAlater solution  
351 (Invitrogen). Kidneys were homogenized in Lysing Matrix C tubes (MPbio), following RNA  
352 extraction with RNeasy (Qiagen). For RNA sequencing of BMDCs, cells were purified using  
353 negative magnetic bead selection (MojoSort Mouse Pan Dendritic Cell Isolation Kit, BioLegend).  
354 2.5x10<sup>6</sup> BMDCs per well were cultured for 6h in 6-well plates in RPMI complete (R10; 10% HI-  
355 FBS, 2mM L-glutamine, 100U/ml Penicillin, 100µ/ml Streptomycin, 50µM β-ME) and 20mg/ml  
356 GM-CSF in presence of 25µg/ml of Curdlan. RNA was isolated using the RNeasy Kit (Qiagen).  
357 RNA sequencing was performed by Novogene Corporation Inc. (Sacramento, USA). mRNA was  
358 purified from total RNA using poly-T oligo-attached magnetic beads. To generate the cDNA library  
359 the first cDNA strand was synthesized using random hexamer primer and M-MuLV Reverse  
360 Transcriptase (RNase H<sup>-</sup>). Second strand cDNA synthesis was subsequently performed using  
361 DNA Polymerase I and RNase H. Double-stranded cDNA was purified using AMPure XP beads  
362 and remaining overhangs of the purified double-stranded cDNA were converted into blunt ends

363 via exonuclease/polymerase. After 3' end adenylation a NEBNext Adaptor with hairpin loop  
364 structure was ligated to prepare for hybridization. In order to select cDNA fragments of 150~200  
365 bp in length, the library fragments were purified with the AMPure XP system (Beckman Coulter,  
366 Beverly, USA). Finally, PCR amplification was performed and PCR products were purified using  
367 AMPure XP beads. The samples were read on an Illumina NovaSeq 6000 with  $\geq 20$  million read  
368 pair per sample.

369 **Downstream Data Processing.** Downstream analysis was performed using a combination of  
370 programs including STAR, HTseq, and Cufflink. Alignments were parsed using Tophat and  
371 differential expressions were determined through DESeq2. KEGG enrichment was implemented  
372 by the ClusterProfiler. Gene fusion and difference of alternative splicing event were detected by  
373 Star-fusion and rMATS. The reference genome of *Mus musculus* (GRCm38/mm10) and gene  
374 model annotation files were downloaded from NCBI/UCSC/Ensembl. Indexes of the reference  
375 genome was built using STAR and paired-end clean reads were aligned to the reference genome  
376 using STAR (v2.5). HTSeq v0.6.1 was used to count the read numbers mapped of each gene.  
377 The FPKM of each gene was calculated based on the length of the gene and reads count mapped  
378 to it. FPKM, Reads Per Kilobase of exon model per Million mapped reads, considers the effect of  
379 sequencing depth and gene length for the reads count at the same time. Differential expression  
380 analysis was performed using the DESeq2 R package (2\_1.6.3). The resulting *P*-values were  
381 adjusted using the Benjamini and Hochberg's approach for controlling the False Discovery Rate  
382 (FDR). Genes with an adjusted *P*-value  $< 0.05$  found by DESeq2 were assigned as differentially  
383 expressed. To allow for log adjustment, genes with 0 FPKM are assigned a value of 0.001.  
384 Correlation were determined using the cor.test function in R with options set alternative = "greater"  
385 and method = "Spearman." To identify the correlation between the differences, we clustered  
386 different samples using expression level FPKM to see the correlation using hierarchical clustering  
387 distance method with the function of heatmap, SOM (Self-organization mapping) and kmeans  
388 using silhouette coefficient to adapt the optimal classification with default parameter in R. We

389 used clusterProfiler R package to test the statistical enrichment of differential expression genes  
390 in KEGG pathways. The high-throughput sequencing data from this study have been deposited  
391 with links to BioProject accession number PRJNA773053 and PRJNA773073 in the NCBI  
392 BioProject database.

393 **RNAscope.** *Scl7a11*, *Gpx4* and *Lyz2* mRNA was detected using RNAscope® *in*  
394 *situ* hybridization. Sections were thawed and postfixed for 15 min in 4% paraformaldehyde (4C°),  
395 and washed in PBS at room temperature. *In situ* hybridization was performed using the  
396 RNAscope® Multiplex v2 Fluorescent Assay (Advanced Cell Diagnostics, Inc.) in strict  
397 accordance with the manufacturer's instruction. Probes used were against  
398 mouse *Slc7a11* (RNAscope® Probe-Mm-C1, Mm-Slc7a11), *Gpx4* (RNAscope® Probe-Mm-C2,  
399 Mm-Gpx4-O1 targeting 12-877 of NM\_008162.4) and *Lyz2* (RNAscope® Probe-Mm-C3, Mm-  
400 *Lyz2*). The commercially available negative control probe was used, which is designed to target  
401 the *DapB* gene from *Bacillus subtilis*. In brief, endogenous peroxidases present in the tissue were  
402 blocked with an RNAscope® hydrogen peroxidase solution. Tissue was washed in distilled water,  
403 then immersed in 100% ethanol, air dried and a hydrophobic barrier was applied to the slides.  
404 The sections were permeabilized with RNAscope® protease III for 30 min at 40°C. Sections were  
405 hybridized with the *Slc7a11*, *Gpx4*, and *Lyz2* probes at 40°C for 2 h. This was followed by a series  
406 of amplification incubation steps: Amp 1, 30 min at 40°C; Amp 2, 30 min at 40°C; Amp 3, 15 min  
407 at 40°C. Sections were washed with provided washing buffer 2 × 2 min in between each  
408 amplification step. Assignment of Akoya 520 (FITC slc7a11), 570 (Cy3 Gpx4) and 690 (Cy5 Lyz2)  
409 occurred with a peroxidase blocking step sequentially. Finally, DAPI stain was applied and  
410 sections were coverslipped with Invitrogen Prolong Gold antifade mounting medium. Images were  
411 taken with the Leica 3D culture Thunder imaging system. For analysis of two representative  
412 sections of the renal cortex were taken for each section for two sections (total of n=4 per animal).  
413 Images were analyzed using Image J. Each channel was thresholded with the Otsu filter circularity  
414 set to 0.25-1 and particle size set to 10-Infinity. Thresholded images were then analyzed and total

415 counts were used to represent each gene. Each gene was then normalized to total cell count as  
416 assessed by DAPI positive cell count.

417 **Bone marrow isolation and cell differentiation.** Bone marrow cells were flushed from femurs  
418 and tibias using RPMI 1640 medium (Gibco) supplemented with 10% HI-FBS and passed through  
419 a 70  $\mu$ m cell strainer. Bone marrow derived macrophages were generated by growing freshly  
420 isolated bone marrow cells from WT and *EphA2*<sup>-/-</sup> mice in presence of 25ng/ml M-CSF during 7  
421 days in DMEM supplemented with 10% HI-FBS and Pen/Strep (100U/ml and 100 $\mu$ ml  
422 respectively, Gemini Bioproducts) at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub>. Bone  
423 marrow derived dendritic cells were generated by growing freshly isolated bone marrow cells from  
424 WT and *EphA2*<sup>-/-</sup> mice in presence of 20ng/ml GM-CSF during 8 days in RPMI complete (R10) at  
425 37°C in a humidified atmosphere containing 5% CO<sub>2</sub>. BMDC purity was determined by flow  
426 cytometry (>95%).

427 **Neutrophil killing assay.** The capacity of neutrophils to kill *C. albicans* hyphae was determined  
428 using the alamarBlue (Invitrogen) reduction as a measure of fungal inactivation. Neutrophils from  
429 mice were isolated as described above. Neutrophils were incubated in duplicate wells of flat  
430 bottom 96-well plates containing hyphae that had been grown for 3 hours with or without  
431 serum opsonization (2% heat-inactivated mouse serum; Gemini Bio-Products), at a neutrophil  
432 to *C. albicans* ratio of 1:4 at 37°C. After 2.5 hours, the neutrophils were lysed with 0.02% Triton  
433 X-100 in water for 5 minutes, after which the *C. albicans* hyphae were washed twice with PBS  
434 and incubated with 1 x alamarBlue (Invitrogen) for 18 hours at 37°C. Optical density at a  
435 wavelength of 570nm and 600nm was determined. Neutrophil killing capacity was calculated as  
436 the amount of alamarBlue reduced by wells containing *C. albicans* hyphae incubated with and  
437 without neutrophils.

438 **Macrophage killing assay.** Bone marrow-derived macrophages were generated as described  
439 above. Macrophage killing of *C. albicans* yeast was determined by CFU enumeration. Briefly,  
440 unopsonized *C. albicans* SC5314 yeast cells were incubated with BMDMs in a 1:1 ratio for 6 and

441 12 hours, respectively. Macrophages were lysed with 0.02% Triton X-100 in ice-cold water for  
442 5 minutes, diluted and remaining *Candida* cells were quantitatively cultured. To determine the  
443 effect of ferroptosis inhibition during killing BMDMs were incubated with 10  $\mu$ M Fer-1 or 50ng/ml  
444 rmIL-23 for 1 hour prior to infection.

445 **Quantification of ferroptosis *in vitro*.** After 7 days of differentiation BMDMs were collected and  
446 seeded on fibronectin-coated glass coverslips in presence or absence of 10 $\mu$ M Fer-1 or 50ng/ml  
447 rmIL-23, after 1h BMDMs were infected with *C. albicans* SC5314 at MOI 1. After 210 min Bodipy™  
448 581/591 C11 was added at the concentration of 10 $\mu$ M for 30 minutes. Cells were fixed using 2%  
449 paraformaldehyde diluted in PBS. After washing the coverslip with PBS, cells were mounted on  
450 microscopic glass using ProLong Gold Antifade Mountant with DAPI. The total fluorescent  
451 integrated density of the reduced form of Bodipy 581/591 C11 was quantified using ImageJ (v1.8).  
452 To measure individual cellular areas and mean fluorescence, an outline was drawn around each  
453 cell, along with several adjacent background readings. Total corrected cellular fluorescence  
454 (TCCF) was calculated using the following formula. Integrated density - (area of selected cell  $\times$   
455 mean fluorescence of background readings).

456 In another experiment we quantified 4HNE during macrophage-*C. albicans* interactions.  
457 After 240 min cells were fixed, washed, and permeabilized following staining with anti-4HNE  
458 (ab46545; Abcam). TCFF was of 4HNE was determined as described above.

459 **Macrophage survival *in vitro*.** 1x10<sup>6</sup> BMDMs seeded in 24 well plates were incubated with *C.*  
460 *albicans* (MOI 1 and 5, respectively) in presence or absence of 10 $\mu$ M Fer-1 or 50ng/ml IL-23.  
461 After 4 hours BMDMs were harvested and stained with an antibody against F4/80 (BM8,  
462 Biolegend) and propidium iodide (BD Biosciences). The stained cells were analyzed on a  
463 FACSymphony system (BD Biosciences).

464 **Renal tubular epithelial damage.** Primary renal proximal tubule epithelial cells (PCS-400-010,  
465 ATCC) in a 24-well plate were loaded with <sup>51</sup>Cr overnight. The next day, the cells were incubated  
466 with 10  $\mu$ M Fer-1 or diluent, and then infected with *C. albicans* at a multiplicity of infection of 10.

467 After 8 hours, the medium above the cells was collected and the epithelial cells were lysed with  
468 RadiacWash (Biodex). The amount of  $^{51}\text{Cr}$  released into the medium and remaining in the cells  
469 was determined with a gamma counter, and the percentage of  $^{51}\text{Cr}$  released in the infected cells  
470 we compared to the release by uninfected epithelial cells. The experiment was performed 3 times  
471 in triplicate.

472 **Cytokine measurement *in vitro*.** BMDMs were stimulated for 6 and 12 hours with *C. albicans*  
473 (MOI 1). RTECs were simulated with *C. albicans* for 12 hours (MOI 5). BMDCs were stimulated  
474 with curdlan (50  $\mu\text{g}/\text{mL}$ ; Invivogen) or LPS (1  $\mu\text{g}/\text{mL}$ , Sigma Aldrich) for 24 hours. Supernatant  
475 were collected and cytokines were measured with Luminex Bead array (R&D Systems) or ELISA  
476 (TNF $\alpha$  #DY410, and IL-23 #D2300B; R&D Systems). To determine the effect of JAK and PPAR  
477 signaling in DCs, BMDCs were incubated with Ruxolitinib (1 $\mu\text{M}$ ; Selleck Chemicals),  
478 Rosiglitazone (10  $\mu\text{M}$ ; Selleck Chemicals), and GW9662 (10  $\mu\text{M}$ ; Selleck Chemicals) for 1 hour  
479 prior stimulation.

480 **Quantification and statistical analysis.** At least three biological replicates were performed for  
481 all *in vitro* experiments unless otherwise indicated. Data were compared by Mann-Whitney  
482 corrected for multiple comparisons using GraphPad Prism (v. 9) software. P values  $< 0.05$  were  
483 considered statistically significant.

484 **Data Availability.** The authors declare that the data supporting the findings of this study are  
485 available within the paper, the accompanying supplementary information files, and the source  
486 data (Source Data file).

487 **Acknowledgements.** MS is supported by NIH grant R00DE026856, an American Association of  
488 Immunologists Careers in Immunology Fellowship, and a Lundquist Seed grant. MSL is supported  
489 by the Division of Intramural Research of the NIAID. RTW is supported by NIH grant  
490 R15AI133415, and NJ by the Francis family foundation and by NIH National Center for Advancing  
491 Translational Science (NCATS) UCLA CTSI Grant Number KL2TR001882. The content is solely

492 the responsibility of the authors and does not necessarily represent the official views of the  
493 National Institutes of Health.

494 We thank members of the Division of Infectious Diseases at Harbor-UCLA Medical Center  
495 for critical suggestions.

496 **Author contributions.** NM and MS designed the experiments. NM, NVS, DA, NJ, and MS  
497 performed the experiments. NM, NVS, DA, NJ, and MS analyzed the data. MSL and RTW  
498 provided methodology. MS wrote the manuscript. All authors reviewed and edited.

499 **Literature**

- 500 1. Netea, M.G., Joosten, L.A., van der Meer, J.W., Kullberg, B.J. & van de Veerdonk, F.L.  
501 Immune defence against *Candida* fungal infections. *Nat Rev Immunol* **15**, 630-42 (2015).
- 502 2. Lionakis, M.S., Iliev, I.D. & Hohl, T.M. Immunity against fungi. *JCI Insight* **2**, 93156  
(2017).
- 503 3. Jawale, C.V. & Biswas, P.S. Local antifungal immunity in the kidney in disseminated  
504 candidiasis. *Current Opinion in Microbiology* **62**, 1-7 (2021).
- 505 4. Brown, G.D. Innate antifungal immunity: the key role of phagocytes. *Annu Rev Immunol*  
506 **29**, 1-21 (2011).
- 507 5. Dambuza, I.M., Levitz, S.M., Netea, M.G. & Brown, G.D. Fungal Recognition and Host  
508 Defense Mechanisms. *Microbiol Spectr* **5**, 0050-2016 (2017).
- 509 6. Branzk, N. et al. Neutrophils sense microbe size and selectively release neutrophil  
510 extracellular traps in response to large pathogens. *Nat Immunol* **15**, 1017-25 (2014).
- 511 7. Drummond, R.A. et al. CARD9-Dependent Neutrophil Recruitment Protects against  
512 Fungal Invasion of the Central Nervous System. *PLoS Pathog* **11**, e1005293 (2015).
- 513 8. Whitney, P.G. et al. Syk signaling in dendritic cells orchestrates innate resistance to  
514 systemic fungal infection. *PLoS Pathog* **10**, e1004276 (2014).
- 515 9. Jawale, C.V. et al. Restoring glucose uptake rescues neutrophil dysfunction and protects  
516 against systemic fungal infection in mouse models of kidney disease. *Sci Transl Med*  
517 **12**(2020).
- 518 10. Conti, H.R. et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host  
519 defense against oral candidiasis. *J Exp Med* **206**, 299-311 (2009).
- 520 11. Conti, H.R. et al. IL-17 Receptor Signaling in Oral Epithelial Cells Is Critical for  
521 Protection against Oropharyngeal Candidiasis. *Cell Host Microbe* **20**, 606-617 (2016).
- 522 12. Swidergall, M. & Filler, S.G. Oropharyngeal Candidiasis: Fungal Invasion and Epithelial  
523 Cell Responses. *PLoS Pathog* **13**, e1006056 (2017).
- 524 13. Verma, A., Gaffen, S.L. & Swidergall, M. Innate Immunity to Mucosal *Candida* Infections.  
525 *J Fungi (Basel)* **3**, 60 (2017).
- 526 14. Puel, A. et al. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous  
527 candidiasis. *Curr Opin Allergy Clin Immunol* **12**, 616-22 (2012).
- 528 15. Lionakis, M.S. & Levitz, S.M. Host Control of Fungal Infections: Lessons from Basic  
529 Studies and Human Cohorts. *Annu Rev Immunol* **36**, 157-191 (2018).
- 530 16. Lionakis, M.S., Netea, M.G. & Holland, S.M. Mendelian genetics of human susceptibility  
531 to fungal infection. *Cold Spring Harb Perspect Med* **4**(2014).
- 532 17. Swidergall, M. et al. Candidalysin Is Required for Neutrophil Recruitment and Virulence  
533 During Systemic *Candida albicans* Infection. *J Infect Dis* **220**, 1477-1488 (2019).
- 534 18. Carpino, N., Naseem, S., Frank, D.M. & Konopka, J.B. Modulating Host Signaling  
535 Pathways to Promote Resistance to Infection by *Candida albicans*. *Frontiers in Cellular  
536 and Infection Microbiology* **7**(2017).
- 537 19. Lionakis, M.S. et al. Chemokine receptor Ccr1 drives neutrophil-mediated kidney  
538 immunopathology and mortality in invasive candidiasis. *PLoS Pathog* **8**, e1002865  
539 (2012).
- 540 20. Pappas, P.G., Lionakis, M.S., Arendrup, M.C., Ostrosky-Zeichner, L. & Kullberg, B.J.  
541 Invasive candidiasis. *Nat Rev Dis Primers* **4**, 18026 (2018).
- 542 21. Lone, S.A., Wani, M.Y., Fru, P. & Ahmad, A. Cellular apoptosis and necrosis as  
543 therapeutic targets for novel Eugenol Tosylate Congeners against *Candida albicans*.  
544 *Scientific Reports* **10**, 1191 (2020).
- 545 22. Bertheloot, D., Latz, E. & Franklin, B.S. Necroptosis, pyroptosis and apoptosis: an  
546 intricate game of cell death. *Cellular & Molecular Immunology* **18**, 1106-1121 (2021).

548 23. Jorgensen, I., Rayamajhi, M. & Miao, E.A. Programmed cell death as a defence against  
549 infection. *Nature reviews. Immunology* **17**, 151-164 (2017).

550 24. Linkermann, A. et al. Regulated cell death in AKI. *J Am Soc Nephrol* **25**, 2689-701  
551 (2014).

552 25. Tang, D., Kang, R., Berghe, T.V., Vandenabeele, P. & Kroemer, G. The molecular  
553 machinery of regulated cell death. *Cell Research* **29**, 347-364 (2019).

554 26. Kim, E.H., Wong, S.W. & Martinez, J. Programmed Necrosis and Disease: We interrupt  
555 your regular programming to bring you necroinflammation. *Cell Death Differ* **26**, 25-40  
556 (2019).

557 27. Dhuriya, Y.K. & Sharma, D. Necroptosis: a regulated inflammatory mode of cell death.  
558 *Journal of Neuroinflammation* **15**, 199 (2018).

559 28. Chen, X., Kang, R., Kroemer, G. & Tang, D. Ferroptosis in infection, inflammation, and  
560 immunity. *J Exp Med* **218** (2021).

561 29. Miao, E.A. et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism  
562 against intracellular bacteria. *Nature immunology* **11**, 1136-1142 (2010).

563 30. Wellington, M., Kosekny, K., Sutterwala, F.S. & Krysan, D.J. *Candida albicans* triggers  
564 NLRP3-mediated pyroptosis in macrophages. *Eukaryot Cell* **13**, 329-40 (2014).

565 31. Li, T. et al. TSC1 Suppresses Macrophage Necroptosis for the Control of Infection by  
566 Fungal Pathogen *Candida albicans*. *ImmunoHorizons* **5**, 90-101 (2021).

567 32. Gross, O. et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal  
568 host defence. *Nature* **459**, 433-436 (2009).

569 33. Swidergall, M., Solis, N.V., Lionakis, M.S. & Filler, S.G. EphA2 is an epithelial cell  
570 pattern recognition receptor for fungal beta-glucans. *Nat Microbiol* **3**, 53-61 (2018).

571 34. Swidergall, M. et al. EphA2 Is a Neutrophil Receptor for *Candida albicans* that  
572 Stimulates Antifungal Activity during Oropharyngeal Infection. *Cell Rep* **28**, 423-433 e5  
573 (2019).

574 35. Sun, W. et al. Cutting Edge: EPHB2 Is a Coreceptor for Fungal Recognition and  
575 Phosphorylation of Syk in the Dectin-1 Signaling Pathway. *J Immunol* **206**, 1419-1423  
576 (2021).

577 36. Chen, J. et al. TAGAP instructs Th17 differentiation by bridging Dectin activation to  
578 EPHB2 signaling in innate antifungal response. *Nature Communications* **11**, 1913  
579 (2020).

580 37. Aaron, P.A., Jamklang, M., Uhrig, J.P. & Gelli, A. The blood-brain barrier internalises  
581 *Cryptococcus neoformans* via the EphA2-tyrosine kinase receptor. *Cell Microbiol*  
582 **20** (2018).

583 38. Kottom, T.J., Schaefbauer, K., Carmona, E.M. & Limper, A.H. EphA2 is a Lung Epithelial  
584 Cell Receptor for *Pneumocystis* β-glucans. *J Infect Dis* (2021).

585 39. Swidergall, M. *Candida albicans* at Host Barrier Sites: Pattern Recognition Receptors  
586 and Beyond. *Pathogens* **8**, 40 (2019).

587 40. Swidergall, M. et al. Activation of EphA2-EGFR signaling in oral epithelial cells by  
588 *Candida albicans* virulence factors. *PLOS Pathogens* **17**, e1009221 (2021).

589 41. Phan, Q.T. et al. The Globular C1q Receptor Is Required for Epidermal Growth Factor  
590 Receptor Signaling during *Candida albicans* Infection. *mBio* **12**, e0271621 (2021).

591 42. Höft, M.A., Hoving, J.C. & Brown, G.D. Signaling C-Type Lectin Receptors in Antifungal  
592 Immunity. *Curr Top Microbiol Immunol* **429**, 63-101 (2020).

593 43. Brown, G.D. & Gordon, S. Immune recognition. A new receptor for beta-glucans. *Nature*  
594 **413**, 36-7 (2001).

595 44. Brown, G.D. Dectin-1: a signalling non-TLR pattern-recognition receptor. *Nat Rev  
596 Immunol* **6**, 33-43 (2006).

597 45. de Saint-Vis, B. et al. Human dendritic cells express neuronal Eph receptor tyrosine  
598 kinases: role of EphA2 in regulating adhesion to fibronectin. *Blood* **102**, 4431-40 (2003).

599 46. Finney, A.C. et al. EphA2 Expression Regulates Inflammation and Fibroproliferative  
600 Remodeling in Atherosclerosis. *Circulation* **136**, 566-582 (2017).

601 47. Navarathna, D.H., Roberts, D.D., Munasinghe, J. & Lizak, M.J. Imaging Candida  
602 Infections in the Host. *Methods Mol Biol* **1356**, 69-78 (2016).

603 48. Dunker, C. et al. Rapid proliferation due to better metabolic adaptation results in full  
604 virulence of a filament-deficient *Candida albicans* strain. *Nat Commun* **12**, 3899 (2021).

605 49. Lionakis, M.S., Lim, J.K., Lee, C.C. & Murphy, P.M. Organ-specific innate immune  
606 responses in a mouse model of invasive candidiasis. *J Innate Immun* **3**, 180-99 (2011).

607 50. Norice, C.T., Smith, F.J., Jr., Solis, N., Filler, S.G. & Mitchell, A.P. Requirement for  
608 *Candida albicans* Sun41 in biofilm formation and virulence. *Eukaryot Cell* **6**, 2046-55  
609 (2007).

610 51. Liu, Y., Mittal, R., Solis, N.V., Prasadrao, N.V. & Filler, S.G. Mechanisms of *Candida*  
611 *albicans* trafficking to the brain. *PLoS Pathog* **7**, e1002305 (2011).

612 52. Carvalho, A. et al. Immunity and Tolerance to Fungi in Hematopoietic Transplantation:  
613 Principles and Perspectives. *Frontiers in Immunology* **3**(2012).

614 53. Leavy, O. Macrophages: Early antifungal defence in kidneys. *Nat Rev Immunol* **14**, 6-7  
615 (2014).

616 54. Jae-Chen, S. et al. Mechanism underlying renal failure caused by pathogenic *Candida*  
617 *albicans* infection. *Biomed Rep* **3**, 179-182 (2015).

618 55. Spellberg, B., Ibrahim, A.S., Edwards, J.E., Jr. & Filler, S.G. Mice with disseminated  
619 candidiasis die of progressive sepsis. *J Infect Dis* **192**, 336-43 (2005).

620 56. Singer, E. et al. Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical  
621 applications. *Acta Physiol (Oxf)* **207**, 663-72 (2013).

622 57. Duggan, S., Leonhardt, I., Hunniger, K. & Kurzai, O. Host response to *Candida albicans*  
623 bloodstream infection and sepsis. *Virulence* **6**, 316-26 (2015).

624 58. Su, L., Liu, D., Chai, W., Liu, D. & Long, Y. Role of sTREM-1 in predicting mortality of  
625 infection: a systematic review and meta-analysis. *BMJ Open* **6**, e010314 (2016).

626 59. Jang, H.R. & Rabb, H. Immune cells in experimental acute kidney injury. *Nature*  
627 *Reviews Nephrology* **11**, 88-101 (2015).

628 60. Dimitrova, P., Gyurkovska, V., Shalova, I., Saso, L. & Ivanovska, N. Inhibition of  
629 zymosan-induced kidney dysfunction by tyrphostin AG-490. *Journal of inflammation*  
630 (*London, England*) **6**, 13-13 (2009).

631 61. Khounlotham, M., Subbian, S., Smith, R., 3rd, Cirillo, S.L. & Cirillo, J.D. *Mycobacterium*  
632 tuberculosis interferes with the response to infection by inducing the host EphA2  
633 receptor. *J Infect Dis* **199**, 1797-806 (2009).

634 62. Zhang, Y. et al. mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and  
635 ferroptosis regulation. *Nature Communications* **12**, 1589 (2021).

636 63. Dixon, S.J. & Stockwell, B.R. The Hallmarks of Ferroptosis. *Annual Review of Cancer*  
637 *Biology* **3**, 35-54 (2019).

638 64. Yang, W.S. & Stockwell, B.R. Ferroptosis: Death by Lipid Peroxidation. *Trends in cell*  
639 *biology* **26**, 165-176 (2016).

640 65. Dixon, S.J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell*  
641 **149**, 1060-72 (2012).

642 66. Horwath, M.C. et al. Antifungal Activity of the Lipophilic Antioxidant Ferrostatin-1.  
643 *Chembiochem* **18**, 2069-2078 (2017).

644 67. Nur, S. et al. IL-23 supports host defense against systemic *Candida albicans* infection by  
645 ensuring myeloid cell survival. *PLoS Pathog* **15**, e1008115 (2019).

646 68. Liu, Q. & Wang, K. The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling  
647 enhances the sensitivity of osteosarcoma cells to cisplatin. *Cell Biol Int* **43**, 1245-1256  
648 (2019).

649 69. Brown, C.W., Amante, J.J., Goel, H.L. & Mercurio, A.M. The  $\alpha 6\beta 4$  integrin promotes  
650 resistance to ferroptosis. *The Journal of cell biology* **216**, 4287-4297 (2017).

651 70. Legrand, A.J., Konstantinou, M., Goode, E.F. & Meier, P. The Diversification of Cell  
652 Death and Immunity: Memento Mori. *Mol Cell* **76**, 232-242 (2019).

653 71. Li, J. et al. Ferroptosis: past, present and future. *Cell Death & Disease* **11**, 88 (2020).

654 72. Tang, D., Chen, X., Kang, R. & Kroemer, G. Ferroptosis: molecular mechanisms and  
655 health implications. *Cell Research* **31**, 107-125 (2021).

656 73. Medzhitov, R., Schneider, D.S. & Soares, M.P. Disease tolerance as a defense strategy.  
657 *Science* **335**, 936-41 (2012).

658 74. Doll, S. & Conrad, M. Iron and ferroptosis: A still ill-defined liaison. *IUBMB Life* **69**, 423-  
659 434 (2017).

660 75. Gaschler, M.M. & Stockwell, B.R. Lipid peroxidation in cell death. *Biochemical and  
661 biophysical research communications* **482**, 419-425 (2017).

662 76. Harry, R.S. et al. Metabolic impact of 4-hydroxyneononal on macrophage-like RAW 264.7  
663 function and activation. *Chem Res Toxicol* **25**, 1643-51 (2012).

664 77. Strasser, D. et al. Syk kinase-coupled C-type lectin receptors engage protein kinase C- $\delta$   
665 to elicit Card9 adaptor-mediated innate immunity. *Immunity* **36**, 32-42 (2012).

666 78. Kapralov, A.A. et al. Redox lipid reprogramming commands susceptibility of  
667 macrophages and microglia to ferroptotic death. *Nature Chemical Biology* **16**, 278-290  
668 (2020).

669 79. Sun, T. & Chi, J.T. Regulation of ferroptosis in cancer cells by YAP/TAZ and Hippo  
670 pathways: The therapeutic implications. *Genes Dis* **8**, 241-249 (2021).

671 80. Jaumouillé, V. & Waterman, C.M. Physical Constraints and Forces Involved in  
672 Phagocytosis. *Frontiers in immunology* **11**, 1097-1097 (2020).

673 81. Bain, J.M. et al. Immune cells fold and damage fungal hyphae. *Proceedings of the  
674 National Academy of Sciences* **118**, e2020484118 (2021).

675 82. Cheng, S.-C. et al. mTOR- and HIF-1 $\alpha$ -mediated aerobic glycolysis as metabolic basis  
676 for trained immunity. *Science (New York, N.Y.)* **345**, 1250684-1250684 (2014).

677 83. Vucetic, M., Daher, B., Cassim, S., Meira, W. & Pouyssegur, J. Together we stand, apart  
678 we fall: how cell-to-cell contact/interplay provides resistance to ferroptosis. *Cell Death &  
679 Disease* **11**, 789 (2020).

680 84. Khader, S.A. & Thirunavukkarasu, S. The Tale of IL-12 and IL-23: A Paradigm Shift. *The  
681 Journal of Immunology* **202**, 629-630 (2019).

682 85. Thompson, A. & Orr, S.J. Emerging IL-12 family cytokines in the fight against fungal  
683 infections. *Cytokine* **111**, 398-407 (2018).

684 86. Kim, H.S. et al. Curdlan activates dendritic cells through dectin-1 and toll-like receptor 4  
685 signaling. *Int Immunopharmacol* **39**, 71-78 (2016).

686 87. Parham, C. et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-  
687 12Rbeta1 and a novel cytokine receptor subunit, IL-23R. *J Immunol* **168**, 5699-708  
688 (2002).

689 88. Oppmann, B. et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with  
690 biological activities similar as well as distinct from IL-12. *Immunity* **13**, 715-25 (2000).

691 89. Chen, Y. et al. A study on the risk of fungal infection with tofacitinib (CP-690550), a  
692 novel oral agent for rheumatoid arthritis. *Scientific Reports* **7**, 6779 (2017).

693 90. Tsirigotis, P. et al. Treatment of Experimental Candida Sepsis with a Janus Kinase  
694 Inhibitor Controls Inflammation and Prolongs Survival. *Antimicrobial agents and  
695 chemotherapy* **59**, 7367-7373 (2015).

696 91. Yang, X.O. et al. STAT3 regulates cytokine-mediated generation of inflammatory helper  
697 T cells. *J Biol Chem* **282**, 9358-9363 (2007).

698 92. Lee, P.W. et al. IL-23R-activated STAT3/STAT4 is essential for Th1/Th17-mediated  
699 CNS autoimmunity. *JCI insight* **2**, e91663 (2017).

700 93. Yao, R. et al. Pathogenic effects of inhibition of mTORC1/STAT3 axis facilitates  
701 Staphylococcus aureus-induced pyroptosis in human macrophages. *Cell Communication  
702 and Signaling* **18**, 187 (2020).

703 94. Smith, A.D. et al. Autocrine IL6-Mediated Activation of the STAT3-DNMT Axis Silences  
704 the TNF $\alpha$ -RIP1 Necroptosis Pathway to Sustain Survival and Accumulation of Myeloid-  
705 Derived Suppressor Cells. *Cancer Res* **80**, 3145-3156 (2020).

706 95. Wang, W. et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy.  
707 *Nature* **569**, 270-274 (2019).

708 96. Fadok, V.A. et al. Exposure of phosphatidylserine on the surface of apoptotic  
709 lymphocytes triggers specific recognition and removal by macrophages. *J Immunol* **148**,  
710 2207-16 (1992).

711 97. Klöditz, K. & Fadeel, B. Three cell deaths and a funeral: macrophage clearance of cells  
712 undergoing distinct modes of cell death. *Cell Death Discovery* **5**, 65 (2019).

713 98. Dennehy, K.M., Willment, J.A., Williams, D.L. & Brown, G.D. Reciprocal regulation of IL-  
714 23 and IL-12 following co-activation of Dectin-1 and TLR signaling pathways. *Eur J  
715 Immunol* **39**, 1379-86 (2009).

716 99. Wang, H. et al. Targeting EphA2 suppresses hepatocellular carcinoma initiation and  
717 progression by dual inhibition of JAK1/STAT3 and AKT signaling. *Cell Rep* **34**, 108765  
718 (2021).


719 100. Melillo, J.A. et al. Dendritic Cell (DC)-Specific Targeting Reveals Stat3 as a Negative  
720 Regulator of DC Function. *The Journal of Immunology* **184**, 2638-2645 (2010).

721 101. Lionakis, M.S. et al. CX3CR1-dependent renal macrophage survival promotes Candida  
722 control and host survival. *J Clin Invest* **123**, 5035-51 (2013).

723 102. Millet, N., Solis, N.V. & Swidergall, M. Mucosal IgA Prevents Commensal Candida  
724 albicans Dysbiosis in the Oral Cavity. *Front Immunol* **11**, 555363 (2020).

725


726



727


728 **Figure 1. EphA2 promotes disease progression during disseminated candidiasis. A**  
729 Survival of wild-type and *Dectin-1*<sup>-/-</sup> (*Clec7a*<sup>-/-</sup>) mice infected intravenously with  $2.5 \times 10^5$  SC5314  
730 *C. albicans*. N=6; two independent experiments. **B-C** Survival of wild-type and *EphA2*<sup>-/-</sup> mice  
731 infected intravenously with  $2.5 \times 10^5$  (**B**; N=12; two independent experiments) or  $1.25 \times 10^5$  (**C**; N=8;  
732 two independent experiments) SC5314 *C. albicans*. **D** Survival of bone marrow chimeric mice  
733 following infection with  $2.5 \times 10^5$  SC5314 *C. albicans*. N=7. *EphA2*<sup>+/+</sup> mice reconstituted with  
734 *EphA2*<sup>+/+</sup> BM (WT → WT), *EphA2*<sup>+/+</sup> mice reconstituted with *EphA2*<sup>-/-</sup> BM (KO → WT), *EphA2*<sup>-/-</sup>

735  $\text{E}^+$  mice reconstituted with *EphA2*<sup>+/+</sup> BM (WT→KO), and *EphA2*<sup>-/-</sup> BM to  $\text{E}^+$  and *EphA2*<sup>-/-</sup> mice (KO→KO).  
736 Statistical significance is indicated by \*  $P<0.01$ , and \*\*\*  $P<0.001$ . Mantel-Cox Log-Rank test.  
737 Kidney fungal burden of infected mice after **E** 4 days and **F** 12 hours of infection with  $2.5 \times 10^5$ .  
738 Results are median (N=6) of two independent experiments. ns, no significance. Mann-Whitney  
739 Test. **G** Apoptotic areas per kidney after 4 days of infection determined by TUNEL staining. N=6;  
740 two independent experiments. Statistical significance is indicated by \* $P<0.05$ ; Mann-Whitney  
741 Test. **H** Serum NGAL and **I** TREM1 levels after 3 days of infection. N=6; two independent experiments.  
742 \*\* $P<0.01$ ; Mann-Whitney Test. **J** Survival of wild-type and *EphA2*<sup>-/-</sup> mice injected  
743 intraperitoneally with 750 mg/kg of zymosan. N=5; two independent experiments. Statistical  
744 significance is indicated by \*\*,  $P < 0.01$ . Mantel-Cox Log-Rank test



745  
746


747 **Figure 2. EphA2 deficiency reduces renal neutrophil and monocyte recruitment, but**  
 748 **increases DC accumulation during candidiasis. A-B** Level of indicated cytokines in kidneys  
 749 after 3 days of infection. N=8; two independent experiments. Statistical significance is indicated  
 750 by \*P<0.05; \*\*P<0.01; \*\*\*P<0.001. Mann-Whitney Test. **C** Accumulation of neutrophils,  
 751 monocytes, and macrophages in the kidney of wild type and *EphA2*<sup>-/-</sup> mice after 3 days of  
 752 infection. N=5, two independent experiments. Statistical significance is indicated by; \*P<0.05. ns;  
 753 No Significance. Mann-Whitney Test. **D-E** Representative flow cytometry plots of MHCII  
 754 expression and frequencies of MHCII-expressing cells in infected kidneys after 3 days of  
 755 infection. N=5; two experiments. **F** Accumulation of conventional dendritic cells (cDCs) and  
 756 lymphoid dendritic cells (IDCs) in kidneys of wild type and *EphA2*<sup>-/-</sup> mice after 3 days of infection  
 757 (N=5). Statistical significance is indicated by \*P<0.05; \*\*P<0.01. Mann-Whitney Test.



758  
759

760 **Figure 3. EphA2 promotes ferroptotic host cell death during candidiasis. A** Up- and down  
761 regulated number of genes of KEGG pathways. RNASeq was performed on mRNA isolated from  
762 kidneys of WT and *EphA2*<sup>-/-</sup> mice after 3 days of infection. N=3 per mouse strain. **B** GSEA of


763 ferroptosis pathway genes. Heatmap of ferroptosis gene expression analysis in WT and *EphA2*<sup>-/-</sup>  
764 mice. Normalized enrichment score is shown on Y-axis. **C** Representative RNAscope image of  
765 *SCL7a11*, *GPX4*, and *LYZ2* expression in infected kidneys after 3 days of infection. Scale bar 50  
766 µm. **D-E** Quantification of RNAsope particles. (D) Normalized particles of DAPI<sup>+</sup> nuclei. (E) *GPX4*<sup>+</sup>  
767 particles of *LYZ2* positive and negative cells. N=4 per animal. **F** *GPX4* protein expression in  
768 infected kidneys after 3 days of infection. *GPX4* shown in green, *C. albicans* (Ca) in red. Tissue  
769 is visualized using DAPI. Scale bar 100 µm. **G** Lipid peroxidation in infected kidneys after 3 days  
770 of infection using 4HNE. 4HNE shown in green, *C. albicans* (Ca) in red. Tissue is visualized using  
771 DAPI. Scale bar 100 µm.



772


773 **Figure 4. Ferroptotic cell death exerts inflammation, decreases macrophage-mediated**  
 774 **fungal killing, and promotes disease progression during candidiasis. A-B** Representative  
 775 **images of C11 oxidation of BM-derived macrophages (A) and renal tubular epithelial damage (B)**  
 776 **during *C. albicans* infection. Host cells were infected with an MOI of 1 (BMDMs, 4 hours; RTECs,**  
 777 **2 hours). C BM-derived macrophages were treated with 10 $\mu$ M Fer-1 for 1 hour followed by**  
 778 **interaction with *C. albicans* (MOI 1 and 5) for 4 hours. PI $^+$  (dead) cells were determined by gating**  
 779 **on F4/80 $^+$  cells. N=3; duplicate. \*\* $P$ <0.01; Mann-Whitney Test. D Renal tubular epithelial damage**  
 780 **determined by specific  $^{51}\text{Cr}$  release. N=3; triplicate. \*\*\* $P$ <0.001; Mann-Whitney Test. E *C. albicans***  
 781 **killing of macrophages treated with Fer-1. MOI 1. N=3; triplicate. \* $P$ <0.05; \*\*\* $P$ <0.001; Mann-**  
 782 **Whitney Test. F TNF $\alpha$  secretion of BM-derived macrophages during *C. albicans* infection (MOI 1)**  
 783 **for indicated time points. N=3, duplicate. \*\* $P$ <0.01; Mann-Whitney Test. G CXCL8 and TNF $\alpha$**

784 secretion of RTECs in the presence and absence of Fer-1 during *C. albicans* infection. MOI 5.  
785 \*\*\* $P<0.0001$ ; Mann-Whitney Test. **H-I** Survival of WT mice treated daily with 10 mg/kg Fer-1 or  
786 vehicle control. Inoculum  $1.25\times10^5$  (H) and  $2.5\times10^5$  (I) *C. albicans*. N=5; two independent  
787 experiments per inoculum. \* $P < 0.05$ ; \*\* $P < 0.01$ . Mantel-Cox Log-Rank test.



788  
789

790 **Figure 5. EphA2 signaling decreases IL-23 secretion in BMDCs.** **A** Correlation of IL-23 kidney  
791 levels and cDC infiltration during candidiasis in WT and *EphA2*<sup>-/-</sup> mice. N=5. Pearson correlation  
792 coefficient \*,  $P < 0.05$ . **B** IL-23 levels in supernatants of DCs after 24 hours stimulation with  $\beta$ -  
793 glucan (curdlan). DCs generated from WT and *EphA2*<sup>-/-</sup> mice. N=6, duplicate. \*\*\*\* $P < 0.0001$ ,  
794 Mann-Whitney Test. Ctrl, control; BG,  $\beta$ -glucan; Ca, *C. albicans*. **C** Number of up and down  
795 regulated genes in corresponding KEGG pathways. BMDCs from WT and *EphA2*<sup>-/-</sup> mice (n=3)  
796 were stimulated for 6 hours with 25  $\mu$ g/mL curdlan. **D** DC IL-23 secretion treated with indicated  
797 inhibitors and stimulated with curdlan. 24 hours post stimulation IL-23 levels in supernatants were  
798 measured with ELISA. N=3; duplicate. \*\*\*\* $P < 0.0001$ , Mann-Whitney Test.



799  
800

**Figure 6. IL-23 signaling reduces ferroptosis during *C. albicans* infection.** **A** BM-derived macrophages were infected with *C. albicans* (MOI 1) for 4 hours in the presence and absence of rmIL-23. Total C11ox fluorescence was quantified. Individual cells (N=57-80; 3 independent experiments) were identified and total fluorescence was measured using ImageJ. \*\*\*\*P<0.0001, Mann-Whitney Test. **B** BM-derived macrophages were treated with rmIL-23 for 1 hour followed by interaction with *C. albicans* (MOI 5) for 4 hours. PI<sup>+</sup> (dead) cells were determined by gating on F4/80<sup>+</sup> cells. N=3; duplicate. \*\*P<0.01; Mann-Whitney Test. **C** Macrophages-mediated *C. albicans* killing in the presence and absence of rmIL-23. MOI 1. N=3; triplicate. \*P<0.05; \*\*\*P<0.001; Mann-Whitney Test. **D** TNFα levels were measured in the supernatant of infected macrophages at 6 and 12 hours post-infection. \*\*P<0.01, Mann-Whitney Test. **E** Kaplan-Meier survival analysis of *C. albicans* infected mice treated with vehicle (veh) or rmIL-23. D2 and D4 indicate the time points of rmIL-23 treatment. \*P<0.05, \*\*P<0.01, Mann-Whitney Test. **F** Bacterial load was determined by CFU/g tissue. \*\*P<0.01, Mann-Whitney Test. **G** and **H** Immunofluorescence analysis of ferroptosis markers (GPX4 and 4HNE) and *C. albicans* (Ca) in vehicle (veh) and rmIL-23 treated macrophages. DAPI was used to stain nuclei.

809 Whitney Test **D** TNF $\alpha$  secretion of BM-derived macrophages during *C. albicans* infection (MOI 1)  
810 for indicated time points. N=3, duplicate. \*\* $P<0.01$ ; Mann-Whitney Test. **E** (Top) IL-23 treatment  
811 scheme during disseminated candidiasis. (Bottom) Survival of wild-type mice infected  
812 intravenously with  $2.5 \times 10^5$  SC5314 *C. albicans*. N=7; two independent experiments. Mice were  
813 treated with recombinant murine IL-23 (rmIL-23) or PBS. Statistical significance is indicated by  
814 \*\*\*,  $P < 0.001$ . Mantel-Cox Log-Rank test. **F** Renal fungal burden after 3 days of infection. Single  
815 rmIL-23 treatment at day 2. N=6-7; two independent experiments. Mice were treated with  
816 recombinant murine IL-23 (rmIL-23) or vehicle (veh; PBS). \*\* $P<0.01$ , Mann-Whitney Test. **G**  
817 GPX4 protein expression in infected kidneys after 3 days of infection. Single rmIL-23 treatment at  
818 day 2 relative to infection. GPX4 shown in green, *C. albicans* (Ca) in red. Tissue is visualized  
819 using DAPI. Scale bar 100  $\mu$ m. **H** Lipid peroxidation in infected kidneys after 3 days of infection  
820 using 4HNE. Single rmIL-23 treatment at day 2 relative to infection. 4HNE shown in green, *C.*  
821 *albicans* (Ca) in red. Tissue is visualized using DAPI. Scale bar 100  $\mu$ m.  
822